

PE anti-human IL-10

Catalog # / Size: 3107015 / 25 tests
3107020 / 100 tests

Clone: JES3-9D7

Isotype: Rat IgG1, κ


Immunogen: COS - expressed, recombinant human IL-10

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Formulation: microg format: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Test format: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide, 0.2% (w/v) BSA (USA origin).

Concentration: NULL



LPS-stimulated (20 hours) human monocytes were surface stained with CD14 FITC and then intracellular stained with JES3-9D7 PE

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: **ELISA Capture¹⁻⁵ or ELISPOT Capture⁶:** The purified JES3-9D7 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502) as the detecting antibody and recombinant human IL-10 (Cat. No. 571009) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization^{1-3,9}: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. No. 501407). The JES3-9D7 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Additional reported applications (for the relevant formats) include: immunohistochemical staining¹².
Note: For testing human IL-10 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430601 to 430606) are specially developed and recommended. The JES3-9D7 antibody reacts with human and viral interleukin-10 (IL-10).

Application References:

1. Abrams J, *et al.* 1992. *Immunol. Rev.* 127:5. (ELISA Capture, Neut)
2. Gotlieb W, *et al.* 1992. *Cytokine* 4:385. (ELISA Capture, Neut)
3. Yssel H, *et al.* 1992. *J. Immunol.* 149:2378. (ELISA Capture, Neut)
4. Abrams J. 1995. *Curr. Prot. Immunol.* John Wiley and Sons New York. Unit 6.20. (ELISA Capture)
5. Burdin N, *et al.* 1993. *J. Exp. Med.* 177:295. (ELISA Capture)

6. Klinman D, *et al.* 1994. *Curr. Prot. Immunol.* John Wiley and Sons New York. Unit 6.19. (ELISPOT Capture)
 7. Schaeferli P, *et al.* 2000. *J. Exp. Med.* 192:1553.
 8. Jason J, *et al.* 1999. *Clin. Diagn. Lab Immunol.* 6:73.
 9. Akdis CA, *et al.* 1998. *J. Clin. Invest.* 102:98. (Neut)
 10. Stary G, *et al.* 2011. *J. Immunol.* 186:103. [PubMed](#)
 11. Mason GM, *et al.* 2012. *PNAS.* [PubMed](#)
 12. Smith DR, *et al.* 1994. *Am. J. Pathol.* 145:18. (IHC)
 13. McCarthy NE, *et al.* 2013. *J Immunol.* 191:2752. [PubMed](#)
 14. Lepse N, *et al.* 2014. *Rheumatology.* [PubMed](#)
-

Description: IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRF1. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.

Antigen
References:

1. Fitzgerald K, *et al.* Eds. 2001. *The Cytokine FactsBook.* Academic Press San Diego.
2. de Waal-Malefyt R, *et al.* 1992. *Curr. Opin. Immunol.* 4:314.
3. Howard M, *et al.* 1992. *Immunol. Today.* 13:198.